Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stock is presently standing at about $41.74 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 10 analysts covering the company is $47.50, which suggests the stock could still rise over 12 percent. The highest analyst price target is $66.00, which implies a rally of 42 percent. And a quick view of analyst notes show that 4 are rating the stock a buy while 1 rate IONS a strong buy. There are 7 equity research firms advocating a Hold and 1 consider it Sell.
Goldman analysts provided their view on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) recently. The rating firm issued a Sell rating to this company in a research note released on Mar 10, 2017. Morgan Stanley analysts disclosed their opinion on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) recently. The rating firm gave a Equal-Weight rating to this stock in a research note published on Aug 03, 2016. According to a research note disclosed on N/A, analysts at N/A have lowered their rating on these shares from N/A to N/A.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its SVP, Antisense Research BENNETT C FRANK sold 5,000 company shares for 275000, in a transaction on 2017-03-03. Following the transaction, the SVP, Antisense Research is left with a stake of 14,788 shares, currently valued at $617251. Meanwhile, Chairman and CEO CROOKE STANLEY T sold 12,100 shares worth $617710, through a transaction dated 2017-03-02. Following the completion of the transaction, the insider is left with a stake of 766,467 shares, amounting $31992332.58. IONS COO PARSHALL B LYNNE also sold 4,625 shares, at a stock price of $49.26. This transaction occurred on 2017-03-01 totals $227830. After this transaction, the insider’s stake stands at 25,651 shares, with a market value of $1070673.
Executives hold 0.37 percent of the stock. Christopher F.O. Gabrieli is one of the biggest insider owners in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 155,431 shares which have current market value of around $6487689.94.Dr. Spencer R. Berthelsen,M.D. is another major inside shareholder in the company. The insider owns 88,958 shares as of less than 0.1%, currently worth $3713106.92. Dr. Stanley T. Crooke,M.D.,PhD is ranked as third insider holder of the stock. This insider holds 38,014 shares with a market value around $1586704.36 as of recent close.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Earnings Outlook
In Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s latest quarter, EPS moved to $0.24 from $0.06 in preceding quarter and revenues reached at $160.35M compared to $110.93M. Analysts had expected Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to post net income of about $-0.12 per share on $97.47M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.56 to $1.15. That is compared with the $-0.52 in EPS it reported during the same period a year ago.